ATE226449T1 - Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen - Google Patents

Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen

Info

Publication number
ATE226449T1
ATE226449T1 AT99964038T AT99964038T ATE226449T1 AT E226449 T1 ATE226449 T1 AT E226449T1 AT 99964038 T AT99964038 T AT 99964038T AT 99964038 T AT99964038 T AT 99964038T AT E226449 T1 ATE226449 T1 AT E226449T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparations
associated virus
excipients
compositions
produced therefrom
Prior art date
Application number
AT99964038T
Other languages
German (de)
English (en)
Inventor
Hema S Sista
Yero J Espinoza
Original Assignee
Avigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avigen Inc filed Critical Avigen Inc
Application granted granted Critical
Publication of ATE226449T1 publication Critical patent/ATE226449T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT99964038T 1998-12-03 1999-12-02 Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen ATE226449T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11068998P 1998-12-03 1998-12-03
PCT/US1999/028460 WO2000032233A2 (en) 1998-12-03 1999-12-02 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith

Publications (1)

Publication Number Publication Date
ATE226449T1 true ATE226449T1 (de) 2002-11-15

Family

ID=22334360

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99964038T ATE226449T1 (de) 1998-12-03 1999-12-02 Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen

Country Status (9)

Country Link
EP (1) EP1144009B1 (enExample)
JP (5) JP2002531418A (enExample)
AT (1) ATE226449T1 (enExample)
AU (2) AU773834B2 (enExample)
CA (1) CA2353417C (enExample)
DE (1) DE69903666T2 (enExample)
ES (1) ES2185417T3 (enExample)
PT (1) PT1144009E (enExample)
WO (1) WO2000032233A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002229823B2 (en) * 2001-04-04 2007-02-15 Delsitech Oy Biodegradable carrier and method for preparation thereof
WO2003049763A1 (en) 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
LT2816118T (lt) 2005-05-31 2018-12-10 The Regents Of The University Of Colorado, A Body Corporate Genų pristatymo būdai
US8980610B2 (en) * 2008-11-20 2015-03-17 Biogen Idec Ma Inc. Arginine inactivation of viruses
JP6348064B2 (ja) 2011-11-22 2018-06-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア 効率の高いトランスジーン送達のためのウイルスベクター
EP4008356A1 (en) 2016-03-31 2022-06-08 University of Cincinnati Methods and compositions for the treatment of als
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
WO2018212271A1 (ja) 2017-05-18 2018-11-22 国立大学法人京都大学 脊髄小脳変性症36型の予防又は治療用組成物
CA3084802A1 (en) * 2017-12-05 2019-06-13 Applied Genetic Technologies Corporation Formulation optimization for viral particles
JP7630443B2 (ja) * 2019-04-19 2025-02-17 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
WO2021168362A1 (en) 2020-02-21 2021-08-26 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
EP0933997A4 (en) * 1996-09-06 2000-08-16 Chiron Corp METHODS AND COMPOSITIONS FOR LIVER-SPECIFIC ADMINISTRATION OF THERAPEUTIC MOLECULES USING RECOMBINANT AAV VECTORS

Also Published As

Publication number Publication date
PT1144009E (pt) 2003-01-31
AU2036100A (en) 2000-06-19
JP2002531418A (ja) 2002-09-24
CA2353417C (en) 2008-04-22
ES2185417T3 (es) 2003-04-16
DE69903666T2 (de) 2003-07-03
JP2011046748A (ja) 2011-03-10
JP2016040330A (ja) 2016-03-24
JP5663285B2 (ja) 2015-02-04
AU2004205308A1 (en) 2004-09-23
EP1144009B1 (en) 2002-10-23
CA2353417A1 (en) 2000-06-08
EP1144009A3 (en) 2002-02-06
DE69903666D1 (de) 2002-11-28
AU773834B2 (en) 2004-06-10
EP1144009A2 (en) 2001-10-17
JP2014058578A (ja) 2014-04-03
WO2000032233A2 (en) 2000-06-08
WO2000032233A3 (en) 2001-10-18
JP2017206556A (ja) 2017-11-24

Similar Documents

Publication Publication Date Title
ATE226449T1 (de) Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
DE69940354D1 (de) Adenovirus-formulierungen zur gentherapie
BRPI0309631A2 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3,e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
DE59410380D1 (de) Endosomolytisch wirksame partikel
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
FI971613A7 (fi) Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
WO2000012740A3 (en) Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
EP0710288A4 (en) ADENOVIRAL VECTORS FOR TREATMENT OF HEMOPHILIA
FI951138A0 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
MX9603002A (es) Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos.
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
NO905438L (no) Virusmiddel.
EA199901031A1 (ru) Производные бензимидазола
DK0935609T3 (da) Krystalliserbare præparater omfattende et hepatitis-C-virus-NS3-proteasedomæne/NS4A-kompleks og dermed opnåede krystaller
EP1466001B8 (en) Viruses with enhanced lytic potency medikament
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
BR9909087A (pt) Formulações para proteção de conjugados peg-alfa interferon
NO983946L (no) Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
DE60022499D1 (de) Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
BR9903567A (pt) "composições pesticidas"
ATE255594T1 (de) Hepatitis b inhibitoren
RU2006118106A (ru) Вектор химерного аденовируса типа 5/типа 35

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties